Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Hilleman CEO On Cost Gains From A Simpler Cholera Vaccine

Executive Summary

Hilleman Laboratories is confident that its oral cholera vaccine, with "multi-fold differentiation" can be manufactured at much lower costs than existing products such as Sanofi-owned Shantha Biotechnics Ltd.'s Shanchol and Valneva SE's Dukoral.

Advertisement

Related Content

Latecomer Hilleman Looks To Leverage Cholera Vaccine Advantages
Valneva builds on traveler's vaccine franchise with €45m Dukoral buy
Hilleman CEO on why new cholera vaccine could be 'high impact'

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register